Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations-Reference-Cited by-同舟云学术

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

Published:2021-05-18 Issue:12 Volume:35 Page:3421-3429
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Jain Nitin,Thompson Philip^ORCID,Burger Jan^ORCID,Ferrajoli Alessandra,Takahashi Koichi^ORCID,Estrov Zeev^ORCID,Borthakur Gautam^ORCID,Bose Prithviraj^ORCID,Kadia Tapan^ORCID,Pemmaraju Naveen^ORCID,Sasaki Koji^ORCID,Konopleva Marina^ORCID,Jabbour Elias^ORCID,Garg Naveen,Wang Xuemei,Kanagal-Shamanna Rashmi^ORCID,Patel Keyur^ORCID,Wang Wei^ORCID,Jorgensen Jeffrey,Wang Sa,Lopez Wanda,Ayala Ana,Plunkett William,Gandhi Varsha^ORCID,Kantarjian Hagop^ORCID,O’Brien Susan,Keating Michael,Wierda William G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01280-8.pdf

Reference35 articles.

1. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391:1524–37.

2. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–88.

3. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42.

4. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56:1643–50.

5. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–15.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic lymphocytic leukaemia;The Lancet;2024-08

2. An overview of prognostic markers in patients with CLL;Frontiers in Oncology;2024-05-16

3. Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study);British Journal of Haematology;2024-04-23

4. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL;Blood Advances;2024-02-14

5. Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study);Blood;2023-11-28